Tumor Progression, Early Diagnosis and Prognosis of Melanoma

REFERENCES

• Elder DE, Clark WH Jr, Elenitsas R, et al. The early and intermediate precursor lesions of tumor progression in the melanocytic system: common acquired nevi and atypical (dysplastic) nevi. Semin Diagn Pathol 1993; 10: 18–35.
   PubMed Web of Science ®Google Scholar
• Elder DE, Van Belle PA, Elenitsas R, Halpern A, Guerry D, W. Neoplastic progression and prognosis in melanoma. Semin Cutan Med Surg 1996; 10: 336–48.
   Google Scholar
• Elder DE, Murphy GF. Malignant tumors (melanomas and related lesions). In: Elder DE, Murphy GF, eds. Melanocytic tumors of the skin. Washington, D.C.: Armed Forces Institute of Pathology, 1991: 103–206.
   Google Scholar
• Herlyn M. Structure and function of molecules produced by melanoma cells. In: Herlyn M, ed. Molecular and cellu-lar biology of melanoma. Austin: R.G. Landes Co, 1993: 44–92.
   Google Scholar
• Foulds L. Neoplastic development. London and New York: Academic Press, 1969.
   Google Scholar
• Rous P, Beard JW. The progression to carcinoma of virus-induced papillomas (Shope). J Exp Med 1935; 62: 523–548e.
   PubMedGoogle Scholar
• Nowell PC. The clonal evolution of tumor cell popula-tions. Science 1976; 194: 23.
   PubMed Web of Science ®Google Scholar
• Clark WH. Tumour progression and the nature of cancer. Br J Cancer 1991; 64: 631–44.
   PubMed Web of Science ®Google Scholar
• Moolgavkar SH. Carcinogenesis models: an overview. Ba-sic Life Sci 1991; 58: 387–396 (discussion).
   PubMedGoogle Scholar
• Armitage P, Doll R. The age distribution of cancer and a multistage theory of carcinogenesis. Br J Cancer 1954; 8: 1–12.
   PubMed Web of Science ®Google Scholar
• Cook PJ, Doll R, Fellingham SA. A mathematical model for the age distribution of cancer in man. Int .1- Cancer 1969; 4: 93–112.
   PubMed Web of Science ®Google Scholar
• Peto R, Roe FJ, Lee PN, et al. Cancer and aging in mice and men. Br J Cancer 1975; 32: 411–26.
   PubMed Web of Science ®Google Scholar
• Den Otter W, Koten JW, Van der Vegt BJ, et al. Oncogene-sis by mutations in anti-oncogenes: a view. Anticancer Res 1990; 10: 475–87.
   Google Scholar
• Fearon ER, Vogelstein B. A genetic model for colorectal carcinogenesis. Cell 1990; 61: 759–67.
   PubMed Web of Science ®Google Scholar
• Clark WH Jr, Elder DE, Guerry D, IV, et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984; 15: 1147–65.
   PubMed Web of Science ®Google Scholar
• Halpern AC, Guerry D, IV, Elder DE, et al. A cohort study of melanoma in patients with dysplastic nevi. J Invest Der-matol 1993; 100: 346S–9S.
   Google Scholar
• Tucker MA, Halpern A, Holly EA, et al. Clinically recog-nized dysplastic nevi-a central risk factor for cutaneous melanoma. JAMA 1997; 277: 1439–44.
   PubMed Web of Science ®Google Scholar
• Masri GD, Clark WH Jr, Guerry D, IV, et al. Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J Am Acad Dermatol 1990; 22: 1042–8.
   PubMed Web of Science ®Google Scholar
• Elder DE, Guerry D, IV, Epstein MN, et al. Invasive malignant melanomas lacking competence for metastasis. Am J Dermatopathol 1984; 6 Suppl: 55–61.
   Google Scholar
• Guerry D, W, Synnestvedt M, Elder DE, et al. Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol 1993; 100: 342S–5S.
   Google Scholar
• Clark WH Jr, Elder DE, Guerry D, W, et al. Model predicting survival in stage I melanoma based on tumor progression. JNCI 1989; 81: 1893–904.
   PubMedGoogle Scholar
• Felding-Habermann B, Mueller BM, Romerdahl CA, et al. Involvement of integrin ocV gene expression in human melanoma tumorigenicity. J Clin Invest 1992; 89: 2018–22.
   Google Scholar
• Nip J, Shibata H, Loskutoff DJ, et al. Human melanoma cells derived from lymphatic metastases use integrin v133 to adhere to lymph node vitronectin. J Clin Invest 1992; 90: 1406–13.
   PubMed Web of Science ®Google Scholar
• Bartfeld NS, Pasquale EB, Geltosky JE, et al. The ocv133 integrin associates with a 190-kDa protein that is phosphory-lated on tyrosine in response to platelet-derived growth factor. J Biol Chem 1993; 268: 17270–6.
   PubMed Web of Science ®Google Scholar
• Seftor REB, Seftor EA, Stetler-Stevenson WG, et al. The 72 kDa type IV collagenase is modulated via differential expres-sion of ocv133 and oc5131 integrins during human melanoma cell invasion. Cancer Res 1993; 53: 3411–5.
   Google Scholar
• Seftor REB, Seftor EA, Gehlsen KR, et al. Role of the ocv133 integrin in human melanoma cell invasion. Proc Natl Acad Sci USA 1992; 89: 1557–61.
   PubMed Web of Science ®Google Scholar
• Lafrenie RM, Podor TJ, Buchanan MR, et al. Up-regulated biosynthesis and expression of endothelial cell vitronectin receptor enhances cancer cell adhesion. Cancer Res 1992; 52: 2202–8.
   PubMed Web of Science ®Google Scholar
• Montgomery AMP, Reisfeld RA, Cheresh DA. Integrin ocv133 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci USA 1994; 91: 8856–60.
   Google Scholar
• Hsu M-Y, Shih D-T, Meier F, et al. Adenoviral gene trans-fer of 133 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol 1998 (in press)
   Google Scholar
• Gallagher RP, McLean DI, Yang CP, et al. Suntan, sun-burn, and pigmentation factors and the frequency of ac-quired melanocytic nevi in children: similarities to melanoma: the Vancouver mole study. Arch Dermatol 1990; 126: 770–6.
   PubMed Web of Science ®Google Scholar
• Holman CD, Armstrong BK, Heenan PJ. Relationship of cutaneous malignant melanoma to individual sunlight-expo-sure habits. J Natl Cancer Inst 1986; 76: 403–14.
   Google Scholar
• Easton DF, Cox GM, Macdonald AM, et al. Genetic sus-ceptibility to naevi - a twin study. Br J Cancer 1991; 64: 1164–7.
   PubMed Web of Science ®Google Scholar
• Elder DE, Greene MH, Bondi EE, et al. Acquired melanocytic nevi and melanoma: the dysplastic nevus syn-drome. In: Ackerman AB, ed. Pathology of malignant melanoma. New York: Masson, 1981: 185–216.
   Google Scholar
• Holly EA, Kelly JW, Shpall SN, et al. Number of melanocytic nevi as a risk factor for malignant melanoma. J Am Acad Dermatol 1987; 17: 459–68.
   PubMed Web of Science ®Google Scholar
• Klein LJ, Barr RJ. Histologic atypia in clinically benign nevi. A prospective study. J Am Acad Dermatol 1990; 22: 275–82.
   PubMed Web of Science ®Google Scholar
• Clark WH Jr, Reimer RR, Greene MH, et al. Origin of familial melanomas from heritable melanocytic lesions. Arch Dermatol 1978; 114: 732–8.
   PubMedGoogle Scholar
• Reimer RR, Clark WH Jr, Greene MH, et al. Precursor lesions in familial melanoma. A new genetic preneoplastic syndrome. JAMA 1978; 239: 744–6.
   Google Scholar
• Elder DE, Goldman LI, Goldman SC, et al. Dysplastic nevus syndrome: a phenotypic association of sporadic cuta-neous melanoma. Cancer 1980; 46: 1787–94.
   PubMed Web of Science ®Google Scholar
• Lynch HT, Frichot BCIII, Lynch JF. Familial atypical multiple mole-melanoma syndrome. J Med Genet 1978; 15: 352–6.
   Google Scholar
• MacKie RM, Freudenberger T, Aitchison TC: Personal risk-factor chart for cutaneous melanoma. Lancet 1989; 2: 487–90.
   PubMed Web of Science ®Google Scholar
• Grob JJ, Andrac L, Romano MH, et al. Dysplastic naevus in non-familial melanoma. A clinicopathological study of 101 cases. Br J Dermatol 1988; 118: 745–52.
   PubMed Web of Science ®Google Scholar
• Kopf AW, Friedman RJ, Rigel DS. Atypical mole syn-drome. J Am Acad Dermatol 1990; 22: 117–8.
   PubMedGoogle Scholar
• National Institutes of Health: Consensus Development Con-ference. Diagnosis and treatment of early melanoma. JAMA 1992; 268: 1314–1319.
   Google Scholar
• Osterlind A, Tucker MA, Stone BJ, et al. The Danish case-control study of cutaneous malignant melanoma. II. Importance of UV-light exposure. Int J Cancer 1988; 42: 319–24.
   PubMed Web of Science ®Google Scholar
• Nordlund JJ, Kirkwood J, Forget BM, et al. Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects. Cancer Res 1985; 45: 1855–61.
   PubMed Web of Science ®Google Scholar
• Halpern AC, Guerry D, IV, Elder DE, et al. Dysplastic nevi as risk markers of sporadic (non-familial) melanoma: a case-control study. Arch Dermatol 1991; 127: 995–9.
   PubMedGoogle Scholar
• Augustsson A, Stierner U, Rosdahl I, et al. Sun exposure, common and dysplastic nevi in melanoma patients and controls. Abstracts, 2nd International Conference on Melanoma 1989; 34 (Abstract).
   Google Scholar
• Garbe C, Kruger S, Stadler R, et al. Markers and relative risk in a German population for developing malignant melanoma. Int J Dermatol 1989; 28: 517–23.
   PubMed Web of Science ®Google Scholar
• Kraemer KH, Greene MH, Tarone R, et al. Dysplastic naevi and cutaneous melanoma risk (letter). Lancet 1983; 2: 1076–7.
   PubMed Web of Science ®Google Scholar
• Elder DE, Green MH, Guerry D, IV, et al. The dysplastic nevus syndrome: our definition. Am J Dermatopathol 1982; 4: 455–60.
   PubMed Web of Science ®Google Scholar
• Greene MH, Clark WH Jr, Tucker MA, et al. Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. N Engl J Med 1985; 312: 91–7.
   PubMed Web of Science ®Google Scholar
• Friedman RJ, Heilman ER, Rigel DS, et al. The dysplastic nevus. Clinical and pathologic features. Dermatol Clin 1985; 3: 239–49.
   PubMed Web of Science ®Google Scholar
• Elder DE, Murphy GF. Benign melanocytic tumors (nevi). In: Elder DE, Murphy GF, eds. Melanocytic tumors of the skin. Washington, D.C.: Armed Forces Institute of Pathol-ogy, 1991: 5–81.
   Google Scholar
• Ainsworth AM, Folberg R, Reed RJ, et al. Melanocytic nevi, melanocytomas, melanocytic dysplasias, and uncom-mon forms of melanoma. In: Clark WH Jr, Goldman LI, Mastrangelo MJ, eds. Human malignant melanoma. New York: Grune & Stratton, 1979: 167–208.
   Google Scholar
• Clemente C, Cochran A, Elder DE, et al. Histopathologic diagnosis of dysplastic nevi. Concordance among patholo-gists convened by the WHO melanoma programme. Hum Pathol 1991; 22: 313–9.
   Google Scholar
• Grob JJ, Gouvernet J, Aymar D, et al. Count of benign melanocytic nevi as a major risk factor for nonfamilial nodular and superficial spreading melanoma. Cancer 1990; 66: 387–95.
   PubMed Web of Science ®Google Scholar
• Meyer LJ, Goldgar DE, Cannon-Albright LA, et al. Num-ber, size, and histopathology of nevi in Utah kindreds. Cytogenet Cell Genet 1992; 59: 167–9.
   PubMedGoogle Scholar
• Goldgar DE, Cannon-Albright LA, Meyer LJ, et al. Inheri-tance of nevus number and size in melanoma/DNS kindreds. Cytogenet Cell Genet 1992; 59: 200–2.
   PubMedGoogle Scholar
• Green A, Siskind V, Bain C, et al. Sunburn and malignant melanoma. Br J Cancer 1985; 51: 393–7.
   PubMed Web of Science ®Google Scholar
• Augustsson A, Stierner U, Rosdahl I, et al. Common and dysplastic naevi as risk factors for cutaneous malignant melanoma in a Swedish population. Acta Derm Venereol (Stockh) 1991; 71: 518–24.
   PubMed Web of Science ®Google Scholar
• Swerdlow AJ, English J, MacKie RM, et al. Benign melanocytic naevi as a risk factor for malignant melanoma. Br Med J 1986; 292: 1555–9.
   PubMed Web of Science ®Google Scholar
• Tucker MA, Fraser MC, Goldstein AM, et al. The risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol 1992.
   Google Scholar
• Kraemer KH, Tucker M, Tarone R, et al. Risk of cutaneous melanoma in dysplastic nevus syndrome types A and B (letter). N Engl J Med 1986; 315: 1615–6.
   PubMed Web of Science ®Google Scholar
• Rigel DS, Rivers JK, Kopf AW, et al. Dysplastic nevi: markers of increased risk for melanoma. Cancer 1989; 63: 386–9.
   PubMed Web of Science ®Google Scholar
• Dabski K, Milgrom H, Stoll HL Jr. Dysplastic nevus syn-drome: association with multiple primary neoplasms. J Surg Oncol 1986; 32: 113–20.
   Google Scholar
• Pehamberger H, Honigsmann H, Wolff K. Dysplastic nevus syndrome with multiple primary amelanotic melanomas in oculocutaneous albinism. J Am Acad Dermatol 1984; 11: 731–5.
   Google Scholar
• Sigg C, Pelloni F, Schnyder UW. Increased incidence of multiple melanoma in sporadic and familial dysplastic nevus syndrome. Hautarzt 1989; 40: 548–52.
   Google Scholar
• Titus Ernstoff L, Duray PH, Ernstoff MS, et al. Dysplastic nevi in association with multiple primary melanoma. Cancer Res 1988; 48: 1016–8.
   PubMed Web of Science ®Google Scholar
• MacKie RM. Multiple melanoma and atypical melanocytic nevi-evidence of an activated and expanded melanocytic system. Br J Dermatol 1982; 107: 621–9.
   PubMed Web of Science ®Google Scholar
• Vasen HFA, Bergman W, Van Haeringen A, et al. The familial dysplastic nevus syndrome. Natural history and the impact of screening on prognosis. A study of nine families in The Netherlands. Eur J Cancer Clin Oncol 1989; 25: 337–41.
   Google Scholar
• Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA A Cancer J Clin 1985; 35: 130–51.
   Google Scholar
• Rigel DS, Friedman RJ. The rationale of the ABCDs of early melanoma. J Am Acad Dermatol 1993; 29: 1060–1.
   PubMed Web of Science ®Google Scholar
• Elder DE, Guerry D, IV, Epstein MN, et al. Invasive malignant melanomas lacking competence for metastasis. Am J Dermatopathol 1984; 6: 55–62.
   PubMed Web of Science ®Google Scholar
• Jimbow K, Roth SI, Fitzpatrick TB, et al. Mitotic activity in non-neoplastic melanocytes in vivo as determined by histo-chemical, autoradiographic, and electron microscopic stud-ies. J Cell Biol 1975; 66: 663–70.
   PubMed Web of Science ®Google Scholar
• Cook MG, Clarke TJ, Humphreys S, et al. The evaluation of diagnostic and prognostic criteria and the terminology of thin cutaneous melanoma by the CRC Melanoma Pathology Panel. Histopathology 1996; 28: 497–512.
   PubMed Web of Science ®Google Scholar
• Clark WH Jr. A classification of malignant melanoma in man correlated with histogenesis and biologic behavior. In: Advances in the biology of the skin. Vol. VIII. New York: Pergamon Press, 1967: 621–647.
   Google Scholar
• Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172: 902–8.
   PubMed Web of Science ®Google Scholar
• Barnhill RL, Fine JA, Roush GC, et al. Predicting five-year outcome for patients with cutaneous melanoma in a popula-tion-based study. Cancer 1996; 78: 427–32.
   PubMed Web of Science ®Google Scholar
• Clark WH Jr, Elder DE, Guerry D, IV. Dysplastic nevi and malignant melanoma. In: Farmer E, Hood AF, eds. The pathology of the skin. Appleton-Century-Crofts, 1990: 682–754.
   Google Scholar
• Cochran AJ. Method of assessing prognosis in patients with malignant melanoma. Lancet 1968; 2: 1062–4.
   PubMed Web of Science ®Google Scholar
• Schmoeckel C, Braun-Falco O. Prognostic index in malig-nant melanoma. Arch Dermatol 1978; 114: 871–3.
   PubMed Web of Science ®Google Scholar
• Clemente CG, Mihm MG, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 1303–10.
   PubMed Web of Science ®Google Scholar
• Szymik B, Woosley JT. Further validation of the prognostic model for stage I malignant melanoma based on tumor progression. J Cutan Pathol 1993; 20: 50–3.
   PubMed Web of Science ®Google Scholar
• Herlyn M. Molecular and cellular biology of melanoma. Austin/Georgetown: R.G. Landes, 1993.
   Google Scholar
• Kath R, Rodeck U, Menssen HD, et al. Tumor progression in the human melanocytic system. Anticancer Res 1989; 9: 865–72.
   PubMed Web of Science ®Google Scholar
• Herlyn M. Human melanoma: development and progression. Cancer Metastasis Rev 1990; 9: 101–12.
   PubMed Web of Science ®Google Scholar
• Hsu M-Y, Elder DE, Herlyn M. The Wistar (WM) melanoma cell lines. In: Masters JRW, Palsson B, eds. Human cell culture. Vol. 3, Solid Cancers. In press, 1998
   Google Scholar
• Balaban G, Herlyn M, Guerry D, IV, et al. Cytogenetics of human malignant melanoma and premalignant lesions. Can-cer Genet Cytogenet 1984; 11: 429–39.
   PubMed Web of Science ®Google Scholar
• Parmiter AH, Nowell PC. Cytogenetics of melanocytic tu-mors. J Invest Dermatol 1993; 100: 254S–8S.
   Google Scholar
• Koprowski H, Herlyn M, Balaban G, et al. Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma. Somat Cell Mol Genet 1985; 11: 297–302.
   PubMedGoogle Scholar
• Fountain JW, Karayiorgou M, Ernstoff MS, et al. Ho-mozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 1992; 89: 10557–61.
   PubMed Web of Science ®Google Scholar
• Isshiki K, Seng BA, Elder DE, et al. Chromosome 9 deletion in sporadic and familial melanomas in vivo. Oncogene 1994; 9: 1649–53.
   PubMed Web of Science ®Google Scholar
• Cannon-Albright LA, Goldgar DE, Meyer LJ, et al. Assign-ment of a locus for familial melanoma, MLM, to chromo-some 9p13-p22. Science 1992; 258: 1148–52.
   Google Scholar
• Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436–40.
   Google Scholar
• Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nature Genet 1994; 8: 15–21.
   PubMed Web of Science ®Google Scholar
• Dracopoli NC, Harnett P, Bale SJ, et al. Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression. Proc Natl Acad Sci USA 1989; 86: 4614–8.
   PubMed Web of Science ®Google Scholar
• Millikin D, Meese E, Vogelstein B, et al. Loss of het-erozygosity for loci on the long arm of chromosome 6 in human malignant melanoma. Cancer Res 1991; 51: 5449–53.
   PubMed Web of Science ®Google Scholar
• Trent JM. Cytogenetics of human malignant melanoma. Cancer Metastasis Rev 1991; 10: 103–13.
   PubMed Web of Science ®Google Scholar
• Parmiter AH, Balaban G, Clark WH Jr, et al. Possible involvement of the chromosome region 10q24 - q26 in early stages of melanocytic neoplasia. Cancer Genet Cytogenet 1988; 30: 313–7.
   PubMedGoogle Scholar
• Lassam NJ, From L, Kahn HJ. Overexpression of p53 is a late event in the development of malignant melanoma. Can-cer Res 1993; 53: 2235–8.
   Google Scholar
• Albino AP, Nanus DM, Mentle IR, et al. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation pheno-type. Oncogene 1989; 4: 1363–74.
   PubMed Web of Science ®Google Scholar
• Meese E, Meltzer PS, Witkowski CM, et al. Molecular mapping of the oncogene myb and rearrangements in malig-nant melanoma. Genes Chromosomes Cancer 1990; 1: 88–94.
   Web of Science ®Google Scholar
• Yamanishi DT, Buckmeier JA, Meyskens FL, Jr. Expression of c-jun, jun-B, and c-fos proto-oncogenes in human primary melanocytes and metastatic melanomas. J Invest Dermatol 1991; 97: 349–53.
   PubMed Web of Science ®Google Scholar
• Van den Oord JJ, Vandeghinste N, De Ley M, et al. Bc1-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 1994; 145: 294–300.
   PubMed Web of Science ®Google Scholar
• Herlyn M, Balaban G, Bennicelli J, et al. Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst 1985; 74: 283–9.
   PubMedGoogle Scholar
• Rodeck U, Herlyn M. Characteristics of cultured human melanocytes from different stages of tumor progression. Cancer Treat Res 1988; 43: 3–16.
   PubMedGoogle Scholar
• Halaban R, Fan B, Ahn J, et al. Growth factors, receptor kinases, and protein tyrosine phosphatases in normal and malignant melanocytes. J Immunother 1992; 12: 154–61.
   PubMed Web of Science ®Google Scholar
• Becker D, Meier CB, Herlyn M. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J 1989; 8: 3685–91.
   Google Scholar
• Pichon F, Lagarde AE. Autoregulation of MeWo metastatic melanoma cell growth: characterization of intracellular (FGF, MGSA) and secreted (PDGF) growth factors. J Cell Physiol 1989; 140: 344–58.
   PubMed Web of Science ®Google Scholar
• Rodeck U, Melber K, Kath R, et al. Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes. J Invest Dermatol 1991; 97: 20–6.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Moller A, Algermissen B, et al. IL-8 pro-duced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol 1993; 151: 2667–75.
   PubMed Web of Science ®Google Scholar
• Reisfeld RA. International consensus conference on human melanoma antigens. Melanoma Res 1993; 3: 209–17.
   PubMed Web of Science ®Google Scholar
• Albelda SM, Buck CA. Integrins and other cell adhesion molecules. FASEB J 1990; 4: 2868–80.
   PubMed Web of Science ®Google Scholar
• Albelda SM, Mette SA, Elder DE, et al. Integrin distribution in malignant melanoma: association of the 133 subunit with tumor progression. Cancer Res 1990; 50: 6757–64.
   PubMed Web of Science ®Google Scholar
• Klein CE, Steinmayer T, Kaufmann D, et al. Identification of a melanoma progression antigen as integrin VLA-2. J Invest Dermatol 1991; 96: 281–4.
   PubMed Web of Science ®Google Scholar
• Danen EHJ, Van Muijen GNP, Van de Wiel-van Kemenade E, et al. Regulation of integrin-mediated adhesion to laminin and collagen in human melanocytes and in non-metastatic and highly metastatic human melanoma cells. Int J Cancer 1993; 54: 315–21.
   Google Scholar
• Klein CE, Dressel D, Steinmayer T, et al. Integrin (2(1 is upregulated in fibroblasts and highly aggressive melanoma cells in three-dimensional collagen lattices and mediates the reorganization of collagen I fibrils. J Cell Biol 1991; 115: 1427–36.
   PubMed Web of Science ®Google Scholar
• McGregor BC, McGregor JL, Weiss LM, et al. Presence of cytoadhesins (Bb-IIIa-like glycoproteins) on human metastatic melanomas but not on benign melanocytes. Am J Clin Pathol 1989; 92: 495–9.
   PubMed Web of Science ®Google Scholar
• Mortarini R, Anichini A. From adhesion to signaling: roles of integrins in the biology of human melanoma. Melanoma Res 1993; 3: 87–97.
   PubMed Web of Science ®Google Scholar
• Elder DE, Van Belle P, Albelda S, et al. Tumor progression-related reactivity of nevi and melanomas with the 133 integrin subunit evaluated by streptavidin immunochemistry in paraffin sections. Lab Invest 1994 (in press)
   Google Scholar
• Van Belle PA, Elenitsas R, Satyamoorthy K, et al. Progres-sion-related expression of 133 integrin in melanomas and nevi. Hum Pathol 1999 (in press)
   Google Scholar
• Hieken TJ, Farolan M, Ronan SG, et al. Beta3 integrin expression in melanoma predicts subsequent metastasis. J Surg Res 1996; 63: 169–73.
   PubMed Web of Science ®Google Scholar
• Cattoretti G, Becker MHG, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168: 357–63.
   PubMed Web of Science ®Google Scholar
• Carey WP Jr, Van Belle P, Elder DE. Tumor progression-re-lated reactivity of nevi and melanomas with the MIB-1 (Ki-67) antigen evaluated by streptavidin immunohistochem-istry on paraffin sections. Pigment Cell Res 1994; Suppl 3: 18.
   Google Scholar